Motif Bio allowed two method-of-use patents in US

Clinical-stage biopharmaceutical company Motif Bio received a ‘Notice of Allowance’ from the United States Patent and Trademark Office, for patent applications 15/586,021 and 15/586,815, it announced on Wednesday.

The AIM-traded firm said the claims related to the use of iclaprim to treat patients with bacterial infections, including - but not limited to - acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis.

It said the two method of use patents would expire in November 2037.

“These US patents provide additional exclusivity for iclaprim in the treatment of bacterial infections well into 2037,” said chief executive officer Graham Lumsden.

“We are actively building our intellectual property portfolio in the US and other key markets around the globe.”